Share |

Regenera Pharma Ltd, privately-held, clinical-stage (Phase II human studies) pharmaceutical company established in 2008 in Israel.

The Company is developing a novel drug candidate, RPh201, derived from botanical source.

Company currently is focused on Ischemic Optic Neuropathy, the most common optic nerve disorder, as main clinical indication and developing RPh201 for Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) as an Orphan drug designation.


The Companys roadmap is to develop this product for other neurodegenerative indications with multibillion market potential.



May 2015: Investment round concluded

Regenera Pharma Ltd. successfully raised around 3 million USD in its most-recent funding round from its current and new shareholders. This is an additional vote of confidence by ...

February 2014: Regenera Pharma Ltd. has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy.

Based on promising pre-clinical results and in order to demonstrate the clinical efficacy of the RPh201, the Company recently has been initiated the Phase IIa study in patients wit...

First patient dosed in Phase I/IIa study evaluating RPh201 effect on behavior and brain activity in chronic vegetative patients

 After receiving approval from the Israeli Ministry of Health, a collaborative Phase I/IIa study in Chronic Vegetative State (CVS) patients has been initiated by Regenera Phar...

January 2012: Regenera Pharma Ltd. initiates dual-centre, Phase I/IIa study in healthy volunteers and patients with Alzheimer’s Disease to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201

  Regenera Pharma Ltd. has received approval from Health Canada to initiate a Phase I study in healthy volunteers followed by Phase I/IIa study in patients with moderate-to...
Regenera Pharma Ltd ©